Reply to G. Sonpavde et al

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages

  De Santis, Maria ^a   Sylvester, Richard ^b   Bellmunt, Joaquim ^c  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b EORTC DATA CENTER   (Belgium)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADVANCED CANCER; CANCER SURVIVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LETTER; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; URINARY TRACT CANCER; UROTHELIUM CANCER;

EID: 79951938430     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.3779     Document Type: Letter

References (11)

1. Sonpavde G, Galsky MD, Vogelzang NJ: First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: Should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol 28:e441-e442, 2010
2. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II - Results of EORTC study 30986. J Clin Oncol 27:5634-5639, 2009
3. Dash A, Galsky MD, Vickers AJ, et al: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506-513, 2006 (Pubitemid 44107210)
4. Bellmunt J, Choueiri TK, Fougeray R, et al: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850-1855, 2010
5. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
6. Bellmunt J, Albanell J, Paz-Ares L, et al: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751-757, 2002 (Pubitemid 34839666)
7. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005 (Pubitemid 46224062)
8. Bellmunt J, Théodore C, Demkov T, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
9. Vaughn DJ, Srinivas S, Stadler WM, et al: Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 115:4110-4117, 2009
10. Sternberg CN, de Mulder P, Schornagel JH, et al: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54, 2006 (Pubitemid 41814532)
11. Bellmunt J, Salhi Y: Reply to G. Sonpavde, et al. J Clin Oncol 28:e208, 2010